Therapeuticsmd Stock Fundamentals
| TXMD Stock | USD 0.87 0.01 1.16% |
TherapeuticsMD fundamentals help investors to digest information that contributes to TherapeuticsMD's financial success or failures. It also enables traders to predict the movement of TherapeuticsMD Stock. The fundamental analysis module provides a way to measure TherapeuticsMD's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to TherapeuticsMD stock.
At present, TherapeuticsMD's Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Total Other Income Expense Net is expected to grow to about 738 K, whereas Total Revenue is forecasted to decline to about 1.4 M.
TherapeuticsMD | Select Account or Indicator |
TherapeuticsMD Company Return On Equity Analysis
TherapeuticsMD's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current TherapeuticsMD Return On Equity | -0.14 |
Most of TherapeuticsMD's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, TherapeuticsMD is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
TherapeuticsMD Total Stockholder Equity
Total Stockholder Equity |
|
At present, TherapeuticsMD's Total Stockholder Equity is projected to decrease significantly based on the last few years of reporting.
Based on the latest financial disclosure, TherapeuticsMD has a Return On Equity of -0.1439. This is 99.4% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The return on equity for all United States stocks is 53.58% lower than that of the firm.
TherapeuticsMD Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining TherapeuticsMD's current stock value. Our valuation model uses many indicators to compare TherapeuticsMD value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across TherapeuticsMD competition to find correlations between indicators driving TherapeuticsMD's intrinsic value. More Info.TherapeuticsMD is rated fifth in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, TherapeuticsMD's Return On Equity is projected to drop based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value TherapeuticsMD by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.TherapeuticsMD Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses TherapeuticsMD's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of TherapeuticsMD could also be used in its relative valuation, which is a method of valuing TherapeuticsMD by comparing valuation metrics of similar companies.TherapeuticsMD is currently under evaluation in return on equity category among its peers.
TherapeuticsMD Fundamentals
| Return On Equity | -0.14 | ||||
| Return On Asset | -0.0665 | ||||
| Profit Margin | (2.08) % | ||||
| Operating Margin | (1.57) % | ||||
| Current Valuation | 12.27 M | ||||
| Shares Outstanding | 11.53 M | ||||
| Shares Owned By Insiders | 1.92 % | ||||
| Shares Owned By Institutions | 30.60 % | ||||
| Number Of Shares Shorted | 155.75 K | ||||
| Price To Earning | (10.22) X | ||||
| Price To Book | 0.37 X | ||||
| Price To Sales | 6.21 X | ||||
| Revenue | 1.3 M | ||||
| Gross Profit | 1.6 M | ||||
| EBITDA | (8.4 M) | ||||
| Net Income | (10.28 M) | ||||
| Cash And Equivalents | 27.08 M | ||||
| Cash Per Share | 2.86 X | ||||
| Total Debt | 8.01 M | ||||
| Debt To Equity | 0.67 % | ||||
| Current Ratio | 0.57 X | ||||
| Book Value Per Share | 2.35 X | ||||
| Cash Flow From Operations | (48.14 M) | ||||
| Short Ratio | 2.84 X | ||||
| Earnings Per Share | (0.35) X | ||||
| Price To Earnings To Growth | (0.73) X | ||||
| Target Price | 5.0 | ||||
| Beta | 1.18 | ||||
| Market Capitalization | 9.91 M | ||||
| Total Asset | 43.31 M | ||||
| Retained Earnings | (949.64 M) | ||||
| Working Capital | 8.51 M | ||||
| Current Asset | 70.68 M | ||||
| Current Liabilities | 10.67 M | ||||
| Net Asset | 43.31 M |
About TherapeuticsMD Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze TherapeuticsMD's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of TherapeuticsMD using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of TherapeuticsMD based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 1.2 M | 1.1 M | |
| Total Revenue | 1.5 M | 1.4 M | |
| Cost Of Revenue | 1.1 M | 1 M | |
| Stock Based Compensation To Revenue | 1.12 | 0.75 | |
| Sales General And Administrative To Revenue | 0.74 | 0.71 | |
| Research And Ddevelopement To Revenue | 0.09 | 0.09 | |
| Capex To Revenue | 0.01 | 0.01 | |
| Revenue Per Share | 0.11 | 0.10 | |
| Ebit Per Revenue | (7.53) | (7.90) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether TherapeuticsMD is a strong investment it is important to analyze TherapeuticsMD's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact TherapeuticsMD's future performance. For an informed investment choice regarding TherapeuticsMD Stock, refer to the following important reports:Check out TherapeuticsMD Piotroski F Score and TherapeuticsMD Altman Z Score analysis. For information on how to trade TherapeuticsMD Stock refer to our How to Trade TherapeuticsMD Stock guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of TherapeuticsMD. If investors know TherapeuticsMD will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about TherapeuticsMD listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.35) | Revenue Per Share | Quarterly Revenue Growth (0.47) | Return On Assets | Return On Equity |
The market value of TherapeuticsMD is measured differently than its book value, which is the value of TherapeuticsMD that is recorded on the company's balance sheet. Investors also form their own opinion of TherapeuticsMD's value that differs from its market value or its book value, called intrinsic value, which is TherapeuticsMD's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because TherapeuticsMD's market value can be influenced by many factors that don't directly affect TherapeuticsMD's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between TherapeuticsMD's value and its price as these two are different measures arrived at by different means. Investors typically determine if TherapeuticsMD is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, TherapeuticsMD's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.